Print
Email
Print Edition StoriesThursday, March 4, 2010
BioVex begins trials for genital herpes vaccine
By Mass High Tech staff
MHT's Julie Donnelly: Pharmaceuticals find drug development partners in colleges
Funding drugs for rare diseases
MHT's Julie Donnelly: Life science startups finding investments
BioVex Inc., a Woburn-based developer of cancer and infectious disease drugs and vaccines, has begun its Phase 1 clinical trial of its genital herpes vaccine, ImmunoVAXHSV2.
The trial, led by Simon Barton and located in the U.K. at the Chelsea and Westminster Hospital, uses healthy patients in an ascended dose trial to measure the safety and immune response of the live attenuated vaccine candidate.
If the vaccine shows promise from the Phase 1 study, BiOVex founder and chief technology officer Robert Coffin said the company would move the vaccine candidate into later stage efficiency trials.
ImmunoVEXHSV2 is made to express 76 of about 80 proteins found in HSV-2, the causative agent of genital herpes.
BioVex announced at the beginning of the year that it had named Tim Hanke as its vice president of commercial operations, responsible for moving the company’s “oncolytic vaccine” OncoVEX GM-CSF product to commercialization.
BioVex has its headquarters in Woburn and maintains its research and development facility in Oxford, England.
Add your comment, and share it via Facebook, LinkedIn, Yahoo and more. Edit your Disqus profile settings.
RSS Feeds
